Ten Medicaid systems vendors have agreed to provide low or no cost services to states over the next two years. The Trump administration said the agreements would save $600 million.
Medicaid contractors strike deals with CMS to help states execute work requirements Read More »
From M&A to surgical robotics and user fee negotiations, the medical device industry has a busy year ahead. Check out MedTech Dive’s roundup of the top medtech trends to watch in 2026.
The Center for Devices and Radiological Health said it is on track to meet review times specified by user fee agreements, despite “resource challenges.”
CDRH on track for review timelines despite staff cuts Read More »
Iskra will help Cleveland Diagnostics scale up commercial adoption of its IsoPSA blood-based test that analyzes the structure of protein biomarkers for prostate cancer signals.
Artificial intelligence could rework the claims and reimbursement process, allowing faster decision-making, reduced errors and billions in savings, according to an Optum executive.
Se han presentado públicamente los resultados del estudio observacional más amplio realizado hasta ahora sobre estrellas masivas fugitivas, que se desplazan por el espacio a velocidades inusualmente altas y se alejan de los lugares en los que nacieron. Este trabajo, que incluye el an&a …
Desentrañando los misterios de las estrellas fugitivas Read More »
Mediante inteligencia artificial, unos científicos han optimizado la extracción limpia de hidrógeno de las aguas residuales. El logro es obra de un equipo internacional encabezado por Anh Tuan Hoang, de la Universidad Tecnológica de Dong Nai en Vietnam. Entre las …
Obtención eficaz de hidrógeno verde de las aguas residuales Read More »
The for-profit hospital operator said it’s implementing a multi-year resilience plan to offset losses. Still, HCA anticipates its full-year earnings this year will skew closely to or exceed 2025 figures.
HCA could lose $1B from ACA subsidy lapse, Medicaid state payment decline Read More »
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026 Read More »
The CEO sat down with Healthcare Dive to discuss the company’s move to accept insurance at BetterHelp, its M&A strategy and how Teladoc is using artificial intelligence.
Chuck Divita on why 2026 is Teladoc’s ‘execution year’ Read More »
